Combined quinacrine and chlorpromazine therapy in fatal familial insomnia.

abstract：OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

journal_title：Clinical neuropharmacology

authors： Elble RJ,Lyons KE,Pahwa R

更新日期：2007-11-01 00:00:00

abstract：:Despite ongoing dispute over the pathophysiologic basis of migraine, the vasospastic theory of pathogenesis has brought to the forefront a promising class of new antimigraine agents, the Ca2+ channel antagonists. Voltage-dependent Ca2+ channels, integral membrane proteins that permit extracellular Ca2+ to enter cells ...

journal_title：Clinical neuropharmacology

authors： Greenberg DA

更新日期：1986-01-01 00:00:00

abstract：:Trazodone is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of depression and insomnia. Fatal overdose is rare and usually occurs when combined with other drugs or alcohol. Only a few lethal cases of pure trazodone overdose have been reported, all attributed to cardiotoxicity. We r...

journal_title：Clinical neuropharmacology

authors： Avila JD

更新日期：2017-09-01 00:00:00

abstract：:A 51-year-old woman became depressed following the death of her father-in-law. She was given 50 mg of milnacipran a day. One week after starting milnacipran, she developed parkinsonism. The milnacipran was increased to 100 mg/d, resulting in a situation where her symptoms of parkinsonism and depression worsened, which...

journal_title：Clinical neuropharmacology

authors： Muraoka T,Oku E,Sugataka K,Yamada S

更新日期：2008-09-01 00:00:00

abstract：:A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...

journal_title：Clinical neuropharmacology

authors： Gomez-Mancilla B,Bédard PJ

更新日期：1993-10-01 00:00:00

abstract：:The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

journal_title：Clinical neuropharmacology

authors： Rascol A,Montastruc JL,Rascol O,Senard JM

更新日期：1986-01-01 00:00:00

abstract：:This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

journal_title：Clinical neuropharmacology

authors： Kemali D

更新日期：1989-01-01 00:00:00

abstract：:In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

journal_title：Clinical neuropharmacology

authors： Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

更新日期：1995-02-01 00:00:00

abstract：:Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

journal_title：Clinical neuropharmacology

authors： Gagiano CA,Hart GA,Bodemer W,Schall R

更新日期：1994-01-01 00:00:00

abstract：OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...

journal_title：Clinical neuropharmacology

authors： Adityanjee,Munshi KR,Thampy A

更新日期：2005-01-01 00:00:00

abstract：:Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to the use of several drugs and illicit drugs. Here, we...

journal_title：Clinical neuropharmacology

authors： Sierra-Hidalgo F,de Pablo-Fernández E

更新日期：2013-03-01 00:00:00

abstract：:We report the case of a 76-year-old, right-handed woman with progressive primary freezing of gait. Despite several therapeutic strategies, she continued to worsen to the point that she became confined to a wheelchair. Treatment with selegiline in doses up to 20 mg/d led to marked improvement of the gait disorder. This...

journal_title：Clinical neuropharmacology

authors： Zúñiga C,Lester J,Cersósimo MG,Díaz S,Micheli FE

更新日期：2006-01-01 00:00:00

abstract：:The mortality risk associated with cardiovascular disease is significantly increased in patients with major depression and panic disorder. The mechanism of this phenomenon is unclear. Thrombin is responsible for platelet aggregation and shape change, and it plays a significant role in the development of thromboembolic...

journal_title：Clinical neuropharmacology

authors： Berk M,Plein H

更新日期：2000-07-01 00:00:00

abstract：:Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study w...

journal_title：Clinical neuropharmacology

authors： Bagheri H,Damase-Michel C,Lapeyre-Mestre M,Cismondo S,O'Connell D,Senard JM,Rascol O,Montastruc JL

更新日期：1999-07-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) is a brain disorder with recognizable periods of onset, course, familial occurrence, epidemiology, phenomenology, and treatment response. Several manifestations of pathophysiology are beginning to be defined, although they may represent intermediate pathophysiology rather than prima...

journal_title：Clinical neuropharmacology

authors： Micallef J,Blin O

更新日期：2001-07-01 00:00:00

abstract：OBJECTIVE:Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS:Electroneurographic assessments with surface electrodes were performed aft...

journal_title：Clinical neuropharmacology

authors： Wohlfarth K,Müller C,Sassin I,Comes G,Grafe S

更新日期：2007-03-01 00:00:00

abstract：OBJECTIVE:The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use. We aimed to determine the dose of amobarbital in the presurgical evaluations of patients with temporal lobe epilepsy. METHODS:A retrospective study ...

journal_title：Clinical neuropharmacology

authors： Bajammal S,Babtain F,Alqadi K,Baeesa S,Kurdi K,Madani N,Al Said Y

更新日期：2020-11-01 00:00:00

abstract：:Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

journal_title：Clinical neuropharmacology

authors： Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

更新日期：1984-01-01 00:00:00

abstract：OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

journal_title：Clinical neuropharmacology

authors： Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

更新日期：2010-05-01 00:00:00

abstract：:In a double-blind, 4 week study, 42 chronic schizophrenic inpatients receiving antipsychotic and antiparkinsonian (AP) drugs for greater than 3 months were either switched to placebo or maintained on biperiden. In the majority of the patients no clinically apparent discomfort was observed, and only two of 21 placebo p...

journal_title：Clinical neuropharmacology

authors： Wada Y,Koshino Y,Yamaguchi N

更新日期：1987-08-01 00:00:00

abstract：OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

journal_title：Clinical neuropharmacology

authors： Kim DW,Oh J

更新日期：2018-01-01 00:00:00

abstract：:In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

journal_title：Clinical neuropharmacology

authors： Fabre LF

更新日期：1989-01-01 00:00:00

abstract：OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

journal_title：Clinical neuropharmacology

authors： Ohta K,Osada T

更新日期：2015-11-01 00:00:00

abstract：:Patients with schizophrenia often experience comorbid obsessive-compulsive syndromes (OCSs). Within these patients, a significant subgroup developed secondary OCS during treatment with antiserotonergic, atypical antipsychotic agents such as clozapine. Although cognitive behavioral therapy and antiobsessive antidepress...

journal_title：Clinical neuropharmacology

authors： Englisch S,Esslinger C,Inta D,Weinbrenner A,Peus V,Gutschalk A,Schirmbeck F,Zink M

更新日期：2009-07-01 00:00:00

abstract：:Intravenous injection of low doses of naloxone was found to reverse the respiratory depression induced by apomorphine in chloralose-anesthesized dogs. Similar results were obtained with haloperidol, whereas yohimbine remained ineffective. These data suggest that apomorphine depresses respiratory rate through a mechani...

journal_title：Clinical neuropharmacology

authors： Montastruc JL,Rascol O,Montastruc P

更新日期：1992-10-01 00:00:00

abstract：:The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

journal_title：Clinical neuropharmacology

authors： Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

更新日期：1985-01-01 00:00:00

abstract：OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

journal_title：Clinical neuropharmacology

authors： Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

更新日期：2005-09-01 00:00:00

abstract：:Therapeutic strategies in the treatment of dystonia consist primarily of pharmacologic, surgical, and supportive approaches. Many recent advances have been made in the treatment of dystonia with newer medications, availability of different botulinum toxins, and surgical procedures. However, these treatment modalities ...

journal_title：Clinical neuropharmacology

authors： Goldman JG,Comella CL

更新日期：2003-03-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：:The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

journal_title：Clinical neuropharmacology

authors： Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

更新日期：2000-03-01 00:00:00